Founder Tarik Soliman, PhD was selected to give two oral presentations in the NIH Innovation Zone (booth #3135) at BIO2024 in San Diego, CA June 3-6.
News
A Manuscript on the Preclinical Development of EXT608 Has Been Published
A manuscript titled, “Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism” by DH Hall, CH Kostyla, LM Hales and TM Soliman has been published in the Journal of Bone Mineral Research Plus.
Extend Biosciences Becomes a Founding Member of the AmCham Abu Dhabi Biotech Committee
Founder Tarik Soliman, PhD travels to Abu Dhabi and Dubai, United Arab Emirates to attend the Partnership Summit: Elevating Business Collaboration in Abu Dhabi as a founding member of the AmCham Biotech Committee.
Abstract Describing the Phase 1 Clinical Trial Data for EXT608 is Selected for the plenary session at ASBMR
Founder Laura Hales, PhD presented the poster titled, “EXT608 for the Treatment of Hypoparathyroidism: Phase 1 Trial Design and Results ” at The American Society for Bone and Mineral Research Annual Meeting in Vancouver, CA.
Click here to view the abstract (purchase/membership required) ->
FDA’s Office of Orphan Products Development Awards Extend Biosciences Grant Funding to Begin Phase 2a Trials for EXT608
An R01 grant was awarded by FDA’s OOPD, who provides funding for clinical trials that advance rare disease medical product development.
Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism
Extend Biosciences announces positive interim clinical data from the Phase 1 trial of EXT608 for the rare disease hypoparathyroidism.
A Second Manuscript Has Been Published on EXT418 for Cancer Cachexia
In collaboration with the laboratory of Jose Garcia, M.D., Ph.D. at the University of Washington, Extend Biosciences publishes a peer-reviewed article titled “EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice”.
A Foundational Manuscript on the D-VITylation Technology Has Been Published
The company’s first manuscript on the D-VITylation technology has been published in the International Journal of Pharmaceutics. It is titled “D-VITylation: Harnessing the biology of vitamin D to improve the pharmacokinetic properties of peptides and small proteins.”
-> A link to the article is here
MassVentures Awards Extend Biosciences with a START II Grant
A START II grant was awarded to Extend Biosciences in support of the Phase 1 clinical trial for EXT608. The company was one of only 5 awardees to receive the second phase of funding.
Extend Biosciences Begins Human Testing of EXT608
The Company is excited to announce that recruiting is ongoing for healthy volunteers to participate in Extend Biosciences’ Phase 1 trial of EXT608. The trial is being funded in-part by NIDDK.
->View the clinical trials.gov entry here